Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
(Thomson Reuters ONE) -
PHILADELPHIA and OXFORD, United Kingdom, 2017-03-22 (GLOBE NEWSWIRE)
-- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to
treat cancer, today announced that it intends to offer and sell American
Depositary Shares ("ADSs") in an underwritten public offering. The offering is
subject to market conditions, and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or terms of the
offering. Adaptimmune also expects to grant the underwriters a 30-day option to
purchase additional ADSs at the public offering price. All of the ADSs in the
offering are to be sold by Adaptimmune, with net proceeds to be used to advance
Adaptimmune's wholly-owned pipeline of SPEAR® T-cell candidates through clinical
trials as well as for other general corporate purposes.
Citigroup, Cowen and Company and Leerink Partners are acting as joint book-
running managers for the offering.
A shelf registration statement on Form S-3 relating to the public offering of
the ADSs described above was declared effective by the Securities and Exchange
Commission ("SEC") on September 12, 2016. The offering is being made only by
means of a written prospectus and prospectus supplement that form a part of the
registration statement. A preliminary prospectus supplement relating to and
describing the terms of the offering will be filed with the SEC and will be
available on the SEC's web site at www.sec.gov. When available, copies of the
preliminary prospectus supplement relating to these securities may also be
obtained by sending a request to: Citigroup Global Markets Inc., c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone:
1-800-831-9146, Cowen and Company, LLC, c/o Broadridge Financial Services, 1155
Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by
calling (631) 274-2806 or Leerink Partners LLC, Attention: Syndicate Department,
One Federal Street, 37th Floor, Boston, MA 02110, email: Syndicate(at)Leerink.com,
telephone: 1-800-808-7525, ext. 6132.
This press release does not constitute an offer to sell or the solicitation of
an offer to buy any of these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer, solicitation
or sale is not permitted.
For readers in the European Economic Area
In any EEA Member State that has implemented the Prospectus Directive, this
communication is only addressed to and directed at qualified investors in that
Member State within the meaning of the Prospectus Directive. The term
"Prospectus Directive" means Directive 2003/71/EC (and amendments thereto,
including Directive 2010/73/EU, to the extent implemented in each relevant
Member State), together with any relevant implementing measure in the relevant
Member State.
For readers in the United Kingdom
This communication, in so far as it constitutes an invitation or inducement to
enter into investment activity (within the meaning of s21 Financial Services and
Markets Act 2000 as amended) in connection with the securities which are the
subject of the offering described in this press release or otherwise, is being
directed only at (i) persons who are outside the United Kingdom or (ii) persons
who have professional experience in matters relating to investments who fall
within Article 19(5) ("Investment professionals") of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) certain
high value persons and entities who fall within Article 49(2)(a) to (d) ("High
net worth companies, unincorporated associations etc") of the Order; or (iv) any
other person to whom it may lawfully be communicated (all such persons in (i) to
(iv) together being referred to as "relevant persons"). The ADSs are only
available to, and any invitation, offer or agreement to subscribe, purchase or
otherwise acquire such ADSs will be engaged in only with, relevant persons. Any
person who is not a relevant person should not act or rely on this document or
any of its contents.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the
development of novel cancer immunotherapy products. The Company's unique SPEAR®
(Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the
engineering of T-cells to target and destroy cancer, including solid tumors.
Adaptimmune has a number of proprietary clinical programs, and is also
developing its NY-ESO SPEAR T-cell program under a strategic collaboration and
licensing agreement with GlaxoSmithKline. The Company is located in
Philadelphia, USA and Oxfordshire, U.K.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking
statements involve certain risks and uncertainties. Such risks and uncertainties
could cause our actual results to differ materially from those indicated by such
forward-looking statements, and include, without limitation: the success, cost
and timing of our product development activities and clinical trials and our
ability to successfully advance our TCR therapeutic candidates through the
regulatory and commercialization processes. For a further description of the
risks and uncertainties that could cause our actual results to differ materially
from those expressed in these forward-looking statements, as well as risks
relating to our business in general, we refer you to our Annual Report on Form
10-K filed with the Securities and Exchange Commission (SEC) on March 13, 2017,
and our other SEC filings. The forward-looking statements contained in this
press release speak only as of the date the statements were made and we do not
undertake any obligation to update such forward-looking statements to reflect
subsequent events or circumstances.
Adaptimmune Contacts
Investor Relations
Will Roberts
T: (215) 825-9306
E: will.roberts(at)adaptimmune.com
Juli P. Miller, PhD
T: (215) 825-9310
E: juli.miller(at)adaptimmune.com
Media Relations
Margaret Henry
T: +44 (0)1235 430036
Cell: +44 (0)7710 304249
E: margaret.henry(at)adaptimmune.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Adaptimmune Therapeutics plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 22.03.2017 - 00:43 Uhr
Sprache: Deutsch
News-ID 531661
Anzahl Zeichen: 7289
contact information:
Town:
Philadelphia
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 142 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares"
steht unter der journalistisch-redaktionellen Verantwortung von
Adaptimmune Therapeutics plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
